LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism
ACS Applied Bio Materials · 2026
DOI: 10.1021/acsabm.5c01892 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2026. Verfasst von Santu Sarkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, North Carolina 27055, United States. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type I, Nanoparticles, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) are extensively utilized in nucleic acid delivery for therapeutic applications because of their biocompatibility and protection of the nucleic acid cargo from degradation during in vivo transport. The nanoscale DNA-based fluoropyrimidine polymer CF10 shows strong efficacy advantages relative to conventional fluoropyrimidine drugs such as 5-fluorouracil (5-FU). In principle, LNP-mediated delivery of CF10 could further enhance its efficacy advantage relative to 5-FU by increasing plasma stability and promoting cell uptake. However, the anticancer activity of CF10 relies on the release of active nucleotides, and it is not clear that LNP-mediated delivery of CF10 preserves dual targeting of thymidylate synthase (TS) and DNA topoisomerase 1 (Top1). This study proposes the incorporation of CF10 into LNPs using chaotic mixing of lipid compositions in a microfluidic chip. Biophysical characterization revealed homogeneous LNP formation with size 80-200 nm in diameter and a zeta-potential of -15 mV, dependent on CF10 concentration. LNPs were stable (tested in PBS) over 4 weeks. In vitro studies showed that LNP formulation increased CF10 uptake specifically into cancer cells, while an immortalized nonmalignant intestinal cell line did not show increased uptake of CF10:LNPs. CF10:LNPs initially colocalized with endosomes, followed by primarily lysosome colocalization at 48 h. CF10:LNPs displayed increased cytotoxicity to cancer cells relative to free CF10, proportional to increased cell uptake. Potent inhibition of TS was achieved consistently with nuclease-mediated release of FdUMP from CF10 in lysosomes. CF10:LNPs also efficiently induced Top1 cleavage complex formation, consistent with perturbation of cellular dNTP pools similar to free CF10. These findings indicate that CF10:LNPs display enhanced anticancer activity relative to free CF10 and preserve CF10's unique TS/Top1 dual targeting mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, North Carolina 27055, United States.
ORCID-Profile: William H Gmeiner
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Sarkar, S., Behl, A., & Gmeiner, W. H. (2026). LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01892
Vancouver
Sarkar S, Behl A, Gmeiner WH. LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.5c01892
BibTeX
@article{Sarkar2026,
author = {Sarkar, Santu and Behl, Akanksha and Gmeiner, William H},
title = {LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism},
journal = {ACS Applied Bio Materials},
year = {2026},
doi = {10.1021/acsabm.5c01892}
}
EUVIMED